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                                                         ABSTRACT: 
 
MicroRNAs (miRNA) are a family of small non-coding RNAs (ncRNAs) having capability of 
regulating gene expression at the post-transcriptional level. MicroRNAs are reported to have 
role in various biological processes like development of embryo, cell proliferation, 
differentiation of cells into other forms, cell death, developmental timing, etc. The role of 
miRNAs as tumor suppressors/oncomiR has already been reported in many cancers. These 
ncRNAs can alter cellular metabolism by directly interacting with target gene transcripts. 
Therefore, miRNA profiling is used for detection and progression of cancer in various field of 
cancer biology such as proliferation, programmed cell death, cancer cell migration and 
angiogenesis. Our study is mainly based on  identification of novel differentially expressed 
targets of MYC regulated miRNAs that are suspected to play role in fibrosarcoma from 
microarray data analysis followed by qRT-PCR for experimental validation of selected pair of 
mRNA (COL1A2 and RRM2). From qRT-PCR study in HT-1080 cell lines, we found that 
COL1A2 and RRM2 are over-expressed in cancer system and their targeting miRNAs are 
down-regulated. The altered expression of COL1A2 and RRM2 might be due to down-
regulation of hsa-let-7g and hsa-let-7b as these miRNAs have target sites within 3/UTR of 
COL1A2 and RRM2. We can assume that these target genes and their miRNAs might be 
playing a role in metastatic in STS by altering the expression of the corresponding mRNA 
through RNA interference mechanism, which can be a probable therapeutic target in 
fibrosarcoma. 
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INTRODUCTION 
Living organisms are comprised of billions of cells. Among these, the undifferentiated 
cells known as stem cells possess unique potential to differentiate into various types of cells 
while maintaining their self-renewal property. When the body requires cells, stem cells start 
to divide to produce a number of cells in order to fulfil the requirement of the body. But when 
these cells keep dividing uncontrollably they create a mass of tissue. Likewise, disorders in 
somatic cells growth also lead to unnecessary tissue accumulation. This mass of additional 
tissue is called as tumor that can be formed in all kinds of tissue and can be of benign or 
malignant in nature. Tumors that are characterized by limited growth are called as benign 
tumors. These tumors are found to be non-motile i.e. do not spread to different parts of the 
body. Another type of tumors which are motile and invade nearby tissues and spread to 
different body parts is called as malignant tumor. Malignant tumors commonly lead to onset 
of cancer. Cancer is a complex disease that affects millions of people and also causes many 
deaths over the years. The cancer etiology includes an array of alterations at genetic and 
epigenetic levels and is characterized by uncontrolled cell growth. At the genetic level, DNA 
damage has been studied as the main cause of cancer. A normal cell (stem cell/somatic cell) 
employs numerous mechanisms to repair DNA damage in order to maintain proper balance in 
cellular integrity and tissue homeostasis. Whereas in case of cancerous cells, DNA damage is 
not properly repaired causing duplication of undesirable cells instead of being eliminated. In 
this way, cancer is a multifactor malady created because of molecular modifications in the 
genome of substantial (stem/somatic) cells.  
Oncogenesis or tumorogenesis is the process of formation of cancer and caused by 
interplay between genetic/epigenetic and environmental factors. There are specific traits 
which are called hallmarks that have the ability to convert normal cells to cancerous cells. 
These hallmarks are i) ability to stimulate their own growth and proliferation, ii) ability to 
withstand the inhibitory signals iii) ability to resist programmed cell death (apoptosis) of their 
own, iv) ability to induce formation of blood vessels (angiogenesis) to supply nutrients to 
tumors, v) ability to multiply forever, vi) capability to attack local tissue and spread to distant 
sites known as. Aside from these six hallmarks, few hallmarks have been added recently to 
the list. These are- i) unusual metabolic pathways, ii) capacity to avoid the immune system, 
iii) chromosome abnormalities and unstable DNA, and iv) inflammation Metastasis is the 
spreading of malignant tumor/cancer. Cancers can be classified depending on the tissue of 
origin. These are – (i) Carcinoma- cancer of epithelial tissue like skin or tissues that cover 
internal organs. The subtypes of this category include adeno-carcinoma, carcinoma of basal 
[2] 
 
cell, carcinoma of squamous cell and transitional cell carcinoma etc., (ii) Leukemia- cancer of 
blood cells or blood-forming cells such as bone marrow, (iii) Lymphoma- cancer of immune 
cells, (iv) Sarcoma- cancer originated from mesenchymal cells, (v) CNS cancer- cancer of 
central nervous system i.e. cancer that originate in the tissue of the brain and spinal cord. 
For the metastatic spread of malignant tumors, the supply of vascular network is very 
important. Angiogenesis and lymhangiogenesis are the processes by which new blood vessels 
are formed and lymphatic system is established respectively. Both of the above processes 
have an important role in the growth and maintenance of cancer cells by providing nutrients, 
oxygen and removing waste products. These phenomena are currently getting special 
consideration in the field of neoplastic vascularisation. Without the vascular network, the 
tumors may get to be necrotic and apoptotic. Vascularisation is essentially a four stage 
process- initially, there will be event of local injury to the basement membranes, then 
angiogenic component movement creating endothelial cells activation followed by 
multiplication and stabilization and lastly the angiogenic components keep on affecting the 
angiogenesis process (Nishida et al., 2006). Metastasis is surely known in diseases of 
epithelial origin; however it is not clearly seen in tumors of mesenchymal source (sarcoma). 
Sarcomas are arised from bone, cartilage or connective tissues and called as 
mesenchymal malignancies (D'Angelo et al.). World Health Organization defined Adult fibro 
sarcoma as malignant neoplasm composed of fibroblasts having variable collagen production 
(Zambo and VeselÃ½). It is also defined by Schultze et al as a tumor originating from 
mesenchymal cell which is having malignant fibroblasts along with collagen (Schultze et al., 
1997). Sarcomas can occur in the form of soft-tissue mass or as a primary or secondary tumor 
of bone. It is characterized by Schultze et al as a tumor beginning from mesenchymal cell 
which is made out of malignant fibroblasts with a collagen foundation (Schultze et al., 1997).  
There are generally two forms of this disease: 
i. Infantile or congenital fibrosarcoma  
It is a sort of soft tissue sarcoma (STS) normally seen in youngsters below one year of age 
(Ainsworth et al.) It displays as a quickly developing mass during childbirth or not long after 
conception. This type of fibrosarcoma is normally moderate developing, furthermore has a 
tendency to be more benign than fibrosarcoma found in adults. 
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ii. Adult form fibrosarcoma 
This type of malady can happen in teenagers, generally between 10 to 15 years. It is more 
dangerous than the infantile form and includes more unpredictable complex treatment. 
Despite the fact that the exact cause of soft tissue tumors and fibrosarcoma is not entirely 
known, certain studies demonstrate that hereditary modifications might be playing a role in 
these abnormal cellular functioning (Helman and Meltzer, 2003)Constrained studies have 
additionally demonstrated a conceivable connection between STS and the advancement of 
other sort of malignancy. A chromosomal alteration has additionally been found in some 
fibrosarcoma (Sreekantaiah et al., 1994). In spite of the fact that sarcoma may emerge from 
any place, the most common primary site is considered as the extremity. During metastasis 
the most well-known site to which the fibrosarcoma spreads is the lungs. As system for 
controlling metastasis are inadequately seen so it is important to know about  the molecular 
mechanism involved in primary tumor cell propagation and its spread to distance destinations 
and consequently to distinguish new molecular targets for tumor treatments. 
MicroRNAs (miRNAs) are group of small ncRNAs having potential role in cancer 
biology including STS. miRNAs are mainly 20-24 nucleotides long. These identify their 
mRNA targets on the basis of sequence complementarity principally to 3/UTR areas and 
hinder protein interpretation or translation. (Schultze et al., 1997) through mRNA debasement 
or translational hindrance. Therefore up-regulation and down-regulation of miRNA has been 
seen to assume a part in disease movement. miRNAs are involved in cellular differentiation 
and proliferation in addition to numerous other functions and their de-regulation leads to 
cancer. Till date many miRNAs have been distinguished in mammals, some of which are 
communicated in a tissue specific and developmental stage specific way. Lately much 
advancement has been done in discovery of this regulatory RNA phenomenon.  
 In normal cell growth, miRNAs play key roles, yet practically it may act either as oncogenes 
or tumor silencers (Zhang et al., 2007) targeting analogous or tumor suppressor genes. 
miRNA have the ability to target transcripts directly and impact cell physiology which is 
found to be involved in cancer etiology.  
In this work, we planned to find out efficient regulations of few selected genes 
(COL1A2 and RRM2) at epigenetic level and that might be associated with soft tissue 
sarcoma oncogenesis. To fulfil our proposed aim, mRNAs were studied which are 
significantly altered in STS and experimental validation of selected mRNAs was done by 
qPCR to predict their correlation of regulations in normal cell line (WI-38) and STS cell line 
(HT-1080). 
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REVIEW AND LITERATURE 
Cancer 
Cancer refers to the excess growth and proliferation of abnormal cells that 
invades different tissues because of the DNA injury or mutation. Blood vascular system and 
lymph nodes helps cancer cells to spread throughout the body. The unwanted additional cells 
aggregate to create mass of cell that is known as tumor. But all type of tumours are not 
dangerous. According to the nature of tumour they will be classified into 2 types (Figure 1) 
i. Benign tumors 
Noncancerous tumors are called as benign tumors. Benign tumour cells do not spread to 
different parts of the body. They can be removed from the body easily. 
ii. Malignant tumors 
Cancerous tumors are malignant in nature. These cells affect nearby tissues and migrate to 
other body parts. The process of spreading of tumor from one site of body to other part is 
known as metastasis. These tumors have nature of converting themselves into distinctive 
cancer. There are more than 100 types of tumors found which influence distinctive parts of 
body. All tumors are unique by its own effects, signs and symptoms and strategies for 
treatment.  
                
 
                    
                  Figure 1: Benign tumors and malignant tumors (Damjanov, 2000.) 
On the basis of origin or location where they develop initially cancer can be classified 
into several types. Thus on the basis of tissues of origin cancers are of the following types 
(Figure 2). 
[5] 
 
 
                                         
                    Figure 2: Different cancer types (http://www.cancerhospitalturkey.com/) 
 
i. Carcinoma: Cancer of epithelial cells which covers external and internal body surface 
is called as carcinoma and these are the most common type of cancer. 
ii. Sarcoma: Cancer arising from mesenchymal cells which support tissues of the body 
for example bone, fat, connective tissue, cartilage, and muscle.  
iii. Lymphoma: This type of cancer originates from the nodes or glands of the lymphatic 
systems and also from tissues of body’s defence system. 
iv. Leukemia: Cancers in which bone marrow is not able to produce new blood cells and 
thus this type of cancer is also called as blood cancer (Stancu et al.). WBC protects 
body from infection, RBCs has role in oxygen transport and mainly prevent anemia 
and platelets help in blood clotting at the time of injury. 
v. Myeloma: This type of cancer grows in plasma cells of bone marrow(Kyle and 
Rajkumar, 2009). There are 2 types of myeloma, among them one is Plasmacytoma in 
which myeloma cells accumulate in a single bone thus forming tumor and second one 
is multiple myeloma in which myeloma cells accumulate in many bone thus 
producing many bone tumors. 
[6] 
 
 
vi. Blastoma: It arises from embryonic tissue. It is found to be more common in children 
than in adult. e.g. Chondroblastoma occurs due to the precursor of chondrocytes. 
SARCOMA 
These are the cancers arising from mesenchymal cells which support tissues of the 
body for example bone, connective tissue, fat and muscle. Sarcoma is quite rare in humans. 
Metastasis is the major cause of death in sarcoma. 2 types of metastasis are there like nodal 
metastasis and distant metastasis. In nodal metastasis through lymph node the cancer cell 
move to distant body parts which is very rare one and other one is distant metastasis which 
generally spread to lungs.  
i. Soft tissue sarcomas: It originates from soft tissues e.g. muscles, blood vessels, fat, 
nerves and fibrous tissue. About 80% of sarcoma arises in soft tissues. According to WHO 
STS occupies 23rd position among all cancer on the basis of occurrence. 
ii. Osteosarcoma: It is generally called as osseous sarcoma which begins in bone. It 
involves 27th position among all tumors on the basis of occurrence. Sarcomas are subdivided 
into different types based on the cell type which makes up the cancer (Table 1). 
Table 1. Subtypes of sarcoma and their origin 
Subtypes of sarcoma  Origin of tumor 
Angiosarcoma Blood or lymphatic vessel 
Chondrosarcoma  Cartilage cells 
Ewing’s sarcoma  Soft tissue or Bone 
Fibrosarcoma  Fibrous tissue 
Leiomyosarcoma  Smooth muscles of abdomen and pelvic parts 
Liposarcoma  Liposarcoma Fat tissue 
Osteosarcoma  Bone 
Rahbdomyosarcoma  Skeletal muscle 
Pleomorphic sarcoma Limb or abdomen 
 
SOFT TISSUE SARCOMA (STS) 
                There are various types of STS, which grows and develop differently. Liposarcoma 
originates from body’s fat which can grow at any part in the body and most commonly affect 
people aged 50-65. Sarcomas that grow in smooth muscle are called leiomyosarcomas. They 
are one of the more regular types of sarcoma and can happen any place in the body, 
particularly in the back of the stomach area (retroperitoneum). Leiomyosarcomas are rare in 
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the soft tissues of the legs or arms. They mainly happen in grown-ups, especially in the 
elderly. 
              Fibrosarcoma is one type of STS. It develops from fibrous tissue which is 
mesenchymal in origin and is formed of fibroblasts, which are histologically predominant 
cells (Loh et al., 2002). 
METASTASIS  
The process of movement of malignant cells through the lymphatic or haematogenous 
circulatory system from primary tumor to distant organs is called as metastasis. Primary 
tumor is the main cause of 10% of deaths in patients but 90% of death is caused due to 
movement of cancer cells (Leber and Efferth, 2009). The sites from where the primary tumor 
will spread and gives rise to secondary malignant tumor is called site of metastasis. The 
determination of these metastatic destinations by the tumor cells in essential site is called 
organ selectivity. Metastasis chooses some useful qualities those aides in invasion and 
additionally the survivability and stability of disease cells. According to recent studies, 
metastasis may happen because of instability of genome due to some oncogenic events like 
DNA damage check points or evasion of growth suppression (Gupta and MassaguÃ©, 2006). 
Metastasis progression mainly include steps like- loss of cell adhesion, transition, 
invasiveness, entry to the circulatory system and colonization at a distant tissue sites 
(Chambers et al., 2002). Recent works based on the genomic-level molecular profiling have 
unrevealed some key regulatory genes whose expression in primary tumor state and the 
metastatic state are found to be strongly co-related (Weigelt et al., 2005). The cancer cells 
acquire the relevant genes to undergo metastasis in different cancer types (Bernards and 
Weinberg, 2002).Metastasis takes place as a result of progressive implication of traits that 
enable the cancer cells to go for migration and invasion at the secondary site (Figure 3).All 
these traits not necessarily should follow this particular order but the factors responsible for 
each step may facilitate the execution of multiple steps simultaneously(Gupta and 
MassaguÃ©, 2006). Metastasis is one of the primary reasons for death in cancer patients. 
Recent reports suggest that microRNA also play an important role in regulating genes 
involved in different steps of metastasis. 
Steps of metastasis 
Metastasis consists of the following steps (Figure 3) 
i. Local invasion 
ii. Intravasation 
iii. Transport through circulation 
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iv. Extravagation 
v. Formation of micro-metastasis 
vi. Colonization 
   
                                Figure 3: Different stages of metastasis (Steeg, 2003) 
MicroRNA 
RNAs include coding as well as ncRNAs that interfere in the activity of other coding 
transcripts. The ncRNAs include small non-coding RNAs (miRNA, siRNA, piRNA, etc.) and 
long non-coding RNAs (lncRNA). The ncRNAs are involved in specific gene silencing or 
gene regulation (Gomes et al.). Among the three types of small ncRNAs, miRNA have some 
pivotal role in normal cell metabolism and its differential expression is supposed to have 
diagnostic and prognostic value in many cancer cases (Lui et al., 2007). 
               miRNAs are of single stranded having 20- 22 nucleotide in length, originated from 
ds hairpin shaped RNA precursors with the help of RNase-III enzyme (Bartel, 2004).miRNAs 
control expression of genes at  post transcriptional level through translational repression or 
degradation of mRNA (Cai et al., 2009). They can regulate different processes like cell 
differentiation, growth and cell death (Esquela-Kerscher and Slack, 2006). For various 
diseases miRNAs are found to be biomarkers and potential therapeutic targets. In cancer cells 
deregulation of miRNA occurs by different mechanisms like amplification, deletion, mutation 
and epigenetic silencing (Garzon et al., 2009).  
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Maturation of miRNAs  
                Primary miRNA (pri-miRNA) precursor molecule is produced by the transcription 
of miRNA (Figure 4). It undergoes cleavage producing precursor miRNA (pre-miRNA) 
which is cleaved to produce miRNA duplex in cytoplasm which contains mature miRNA. 
Then unwinding of duplex occurs as a result of which mature miRNA are released and 
assemble with RISC complex. These mature miRNA then direct gene silencing through 
translational repression or mRNA cleavage. 
 
                                Figure 4: miRNA maturation and function(Yim et al.) 
 
miRNA targeting 
                miRNA generally targets the mRNA for post transcriptional repression and for that 
it binds to 3’ UTR of mRNA. The complementarily between the miRNA seed region and with 
that of target mRNA has a pivotal role in miRNA-mediated gene regulation through miRNA 
targeting. There exist principally three sorts of traditional target binding sites such as 
canonical sites, marginal sites and atypical sites. In the canonical sites, the coupling mainly 
occurs between 2-7 or 2-8 nucleotide position on the miRNA, while for marginal sites it lies 
in the middle of 2-7 or 3-8 nucleotide positions. The supplementary sites are situated at 12-17 
position in addition to the seed region with complete Watson-Crick base pairing. At the same 
time,  compensatory base pairing sites are seen in between 12-19 position regarding wobble 
base pairing in the traditional seed sites in order to compensate the mismatch (Bartel, 2009). 
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miRNA expression profiling in sarcomas 
             miRNA expression profiling in sarcomas has helped in the monitoring of the 
expression of thousands of miRNAs. Presently more than 1000 miRNAs have been identified 
in human. In different carcinomas, sarcoma and hematologic malignancies, analysis of 
miRNAs expression disclosed uniform pattern of specific miRNAs. Due to strong association 
with cancer some miRNAs are also called as oncomiR. For example in gliobalstomas over 
expression of miR-21 is found or in B cell lymphoma, rhadomyosarcoma and liposarcoma, 
microRNA 17-92 cluster found to be up-regulated. Some miRNA clusters which are found to 
be associated with cancer or other disease are seen within chromosomal fragile regions 
resulting in sequence amplification or deletion. As sarcomas are highly heterogeneous in 
nature, it is very difficult to validate sarcoma diagnosis. So for proper diagnosis, prognosis 
and therapeutic intervention of different sarcomas miRNA signature plays an important role. 
Role of TFs in cancer system 
Transcriptional factors can cause cancer either by activating or repressing the target 
genes. MYC (c-myc) is one of the regulatory gene that codes for a transcription factor. The 
transcriptional product of this gene is a multifunctional protein that takes part in cell cycle, 
movement, apoptosis, cell transformation, proliferation, cell-cycle progression, transcription 
and differentiation (Vita and Henriksson, 2006). myc directly can increase translation by 
regulating the expression of various members of the protein synthetic machinery like 
ribosomal proteins and translational initiation factors, including Pol III and rDNA. A 
transformed form of myc is found in numerous tumors, which affects expression of its 
downstream molecules. This prompts the unregulated expression of many genes, some of 
which are included in cell multiplication, and results in the onset of cancer. Malfunctions in 
myc have likewise been found in carcinoma of the cervix, colon, lung and stomach. myc 
regulating miRNAs can either induce or suppress the expression of various mRNA which are 
differentially expressed in STS. myc is consequently seen as a promising target for anti-
cancer drugs (Begley).  
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OBJECTIVES 
Objective 1: 
To identify the list of miRNAs reported to be regulated by myc. 
 
Objective 2: 
To identify myc regulated miRNAs reported in STS and their target genes from different 
databases and build myc-miRNA regulatory network. 
 
Objective 3: 
Microarray expression analysis in fibrosarcoma to identify set of differentially expressed 
(DE) mRNAs and their comparison with myc-miRNA regulatory network. 
i. All myc-miRNA regulated target genes vs. DE genes in fibrosarcoma 
ii. DE myc regulate genes vs. known genes in STS 
Objective 4: 
Identification of anomalous altered expression of novel mRNAs involved in fibrosarcoma and 
experimental validation by qRT-PCR in HT-1080 cell lines. 
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MATERIALS AND METHODS 
General work flow to find out DE novel genes in STS is shown with the help of flow chart 
(Figure 5). 
 
 
         Figure 5: General workflow to find out novel DE genes in STS 
1) Myc regulated miRNA 
 miRNAs transcriptionally regulated by MYC was retrieved from TransmiR database(Wang 
et al.). TransmiR is a database which gives idea about regulation of miRNA-transcription 
factor. This database is free for academic uses. Further the miRNAs obtained from TransmiR 
were mapped to and checked with HMDD database(Lu et al., 2008), PhenomiR(Ruepp et al.) 
and published literature and only the ones relevant to STS were retained for the study.  
[13] 
 
2) miRNA-Target Selection 
To study the downstream gene targets of Myc-miRNA interaction pathway in STS, the 
validated targets of those miRNAs which are regulated by myc were selected from miRecords 
(Xiao et al., 2009), miRBase (Griffiths-Jones et al., 2006) and miRTarbase (Hsu et al.). Total 
numbers of targets were compiled for those miRNAs from all the three databases and a Myc-
miRNA regulatory network was build. The aim was to predict which of these targets were 
also differentially expressed in STS. From analysis of microarray data, alterations in gene 
expression were investigated.  
3) Microarray analysis of gene Expression Data: 
A. Retrieval of mRNA gene expression data 
i. All samples of fibrosarcoma and normal control fat (i.e. all GSMs) present in the GSE 
21122 were taken for analysis. The details of number of samples taken for mRNA 
expression analysis are given in (Table 2).The data were taken in multiples to reduce 
error rate. 
ii. The raw files were downloaded in .CEL format. 
iii. Then the files were unzipped, extracted and renamed as control and test for mRNA 
and miRNA accordingly. 
Table 2. Number of samples taken for mRNA and miRNA expression analysis 
Expression data Sarcoma No. of samples 
mRNA MFH:Myxofibrosarcoma 31 
mRNA Normal fat 9 
 
 
 
B. Analysis of Gene Expression Data 
Agilent’s GeneSpring GX 12.6 software is used for gene expression analysis. This 
software is a powerful microarray expression data analysis tool for fast visualization and 
analysis of different microarrays (gene, miRNA, exon, genome copy number, etc.). Class of 
transcripts showing expression pattern which are correlated with experiment variables are 
identified by using this software. Thus mainly for fulfilling the needs of biologists this tool is 
designed. 
[14] 
 
Performing work in GeneSpring GX 12.6 is organized into projects. In a project a number of 
experiments are involved and again an experiment is composed of samples that are data 
sources. Samples are grouped as test and control and interpretations are done based on the 
defined parameters of sample grouping and finally analysis involves a number of statistical 
steps and corresponding results. 
                 All information on array design along with biological information is found in 
Genespring GX. So for each new array type which is to be analysed, a new technology must 
be installed initially. Technologies created include affymetrix for standard arrays, Agilent and 
Illumina. In GeneSpring following steps are used. 
i. In order to minimize the systematic non-biological differences to reveal true 
biological differences, normalization of data was done, after which profile plot of normalized 
intensity map values are obtained. To standardize each chip for cross comparison, data is 
normalized to 75th percentile of signals intensity. The main purpose is to eliminate 
redundancy and make sure that the data makes sense with minimum number of entities. 
ii. A new experiment was created for analysis of gene expression. The experiment type 
should be specified as Affymetrix. Workflow selected was Guided Workflow. Using choose 
sample option the unzipped samples (both sarcoma and normal fat) were uploaded to the 
experiment in GeneSpring from the saved location in the system. Experimental grouping was 
done to define samples as test and control and assigning a parameter name (e.g. Average). 
iii. By using Filter Probsets by Errors, quality control of samples was done. This was 
done on the raw signal values of all the entities. For filtering, cut off was set at 20 percentile 
of all intensity values and a profile plot of filtered entities was generated. Using the 
normalized signal values and grouped samples by active interpretation box whisker plot is 
generated. 
iv. Significance analysis depending upon experiment grouping was done by performing t-
Test unpaired analysis as 2 groups are there that is control and test along with replicates. For 
computing p-values Benjamini-Hochberg FDR algorithm multiple testing corrections was 
used. The p-value cut off taken was ≤0.05. This reduces the number of false positives or false 
discovery rate. This multiple testing correction is least stringent. Fewer chances of false 
negative genes are there. A p-value of ≤0.05 is taken as significant. 
v. For identifying differentially genes among the cancerous and non-cancerous samples 
which are expressed above a definite threshold, fold change analysis is done. It gives the 
absolute ratio of normalized intensities between the average intensities of grouped sample. 
Fold change cut off is taken ≥2.0. 
[15] 
 
vi. Further 2D hierarchical clustering of the genes expressed >2.0 fold was carried out 
taking average linkage to classify the cancerous and normal control samples and a heat map 
was generated using CLUSTER 3.0 and JAVA tree view. Hierarchical clustering method 
arranges gene in a tree structure based on their similarity. If the items are similar to each 
other then they are connected by short branches and if it is dissimilar then it is connected by 
long braches. 
vii. Genes expressed greater than 2 fold were exported from GeneSpring along with 
normalized signal values, gene symbols, entrez gene IDs etc. The entity list was exported as 
.txt file and later opened with excel for further analysis. 
4) Novel DE gene identification for STS 
DE targets of myc-miRNA in fibrosarcoma were screened out from gene expression study. 
These DE myc-miRNA targets were then compared to known STS genes from Malacard 
disease database(Rappaport et al.) to find out novel mRNAs with anomalous altered expression 
in fibrosarcoma.  
5) Functional annotation of six novel myc-miRNA targets DE  in fibrosarcoma 
myc-miRNA-target pathway provides novel genes which are having altered expression in 
STS. Functional annotation of those genes were done by using Database for Annotation, 
Visualization, and Integrated Discovery (DAVID), version 6.7 (Huang et al., 2008, 2009) 
which is generally used for gene ontology (GO) study. This database records function of 
around 1.5 million unique protein/genes  obtained from about 65,000 species.  
6) Experimental validation 
               Human fibrosarcoma cell line HT-1080 was procured from National Centre for Cell 
Science, Pune, India and the fibroblast cell line WI-38 was obtained from Bose Institute, 
Kolkata, India. The media used for culturing the HT1080 cell line is DMEM (Dulbecco’s 
Modified Eagle’s Medium) with 10% FBS (Fetal Bovine Serum) from HIMEDIA and 1% 
antibiotic solution. The culture flask containing the cell line is kept in CO2 maintained at 5%. 
The media contains phenol red, a pH indicator and when the media is utilize by cells the 
colour of medium changes from red to orange and finally to pale yellow because of change in 
pH. 
 
Cell Culture 
a. Reviving of stored cells 
For reviving cells they are first thawed by drastically reducing the stored cells temperature 
from -80oC to 37oC in a water bath to avoid formation of crystals. 5ml of DMEM was taken 
[16] 
 
in a T25 flask and the thawed cell specimen was pipetted into the flask. The flask was swirled 
gently in order to mix the cells with medium. Centrifuge at 1500rpm for 5min, aspirate the 
supernatant, and then re-suspend the cells in fresh medium. Cells were incubated overnight 
and then checked for their adherence to the flask and the growth medium was replaced. The 
cells are grown in a flask until they are confluent enough or their medium has been utilized 
and they are ready for sub-culture. 
b. Trypsinizing cells 
Trypsinization is a process which uses the proteolytic enzyme trypsin in order to detach the 
cells adherent to the surface of a cell cultured vessel. For trypsinization the medium was 
discarded. Cells were washed with 1X PBS. 1ml 1X trypsin EDTA solution was added. The 
flask was placed in a CO2 incubator at 37
oC for 1 to 2 minute or until all cells were detached. 
Cells were re-suspended in a growth medium having serum. Use medium having the same 
percentage of serum as used for growing the cells. The serum decreases 21 trypsin activities. 
Then cells were pipetted gently up and down and transformed to an RNAase free glass or 
polypropylene centrifuge tube and then centrifugation done at 1500rpm for 5 minute. Then 
the supernatant was aspirated completely and the cells again re-suspended in 1X PBS and 
were counted. The appropriate no. of cells were taken for isolation of RNA by again pelleting 
the cells and removing PBS. 
RNA isolation 
i. mRNA isolation  
For mRNA isolation QIAGEN kit is used. 
First at a maximum of 1 × 107 cells were harvested then appropriate volume of buffer RLT 
was added. 
I. To the lysate, 1 volume of 70% ethanol was added and mixed well by pipetting. 
Immediately proceed to step 3. 
II. 700μl of sample including any precipitation was transferred to an RNeasy mini spin 
column placed in 2ml supplied collection tube. Then the lid was closed and 
centrifuged for 15 sec at ≥ 8000xg.Then flow through was discarded. 
III. To RNeasy spin column 700μl of RW1 was added. Then the lid was closed and 
centrifuged for 15 sec at 8000xg.Then flow through was discarded. 
IV. To RNeasy spin column 500μl of RW1 was added. Then the lid was closed and 
centrifuged for 15 sec at ≥ 8000xg.Then flow through was discarded 
V. To RNeasy spin column 500μl of RW1 was added. Then the lid was closed and 
centrifuged for 2 minute at ≥ 8000xg. 
[17] 
 
VI. In a new 1.5ml collection tube the RNeasy spin column was placed. To the  spin 
column membrane 30-40μl RNase free water was added directly and centrifugation 
was done for 1 minute at ≥ 8000xg in order to elute RNA. 
VII. If the expected RNA yield is more than 30μg, then the step-7 was once again repeated  
by using another 30-50μl of RNase free water or using the elute obtained from step-
7.The collection tube were reused from step-7. 
VIII. The purity and yield of RNA was measured by using Eppendorf NanoDrop. It is a 
cuvette free spectrophotometer which eliminates the requirement for other sample 
containment device. 1μl of sample can be measured with this instrument with high 
reproducibility and accuracy. 1μl of sample was pipetted onto the end of an optic fiber 
cable. The instrument is controlled by software and the data is logged in an archive 
file on PC. 
cDNA Synthesis 
i. mRNA cDNA synthesis  
cDNA Synthesis was done by using Super Script First Standard Synthesis System for RT-
PCR by Invitrogen using oligo dT primer. 
I. Components were mixed and briefly centrifuged before use. 
II. Following components were mixed in a sterile 0.2 or 0.5 tube for each reaction. 
III.  
Components Amount 
RNA (2μg) 4 μl 
10mM dNTP mix 1 μl 
Primer(0.5μg/μl oligo 
(dT)12-18OR 2 μM gene 
specific primer) 
1 μl 
DEPC treated water 4μl 
IV. Mixture of RNA/Primer was incubated at 65oC for 5 minute and then placed on ice for 
at least 1 minute. 
V. Following 2X reaction was prepared in a separation tube by using each component in 
the indicated order. 
Component   1RXn 10RXn 
10X RT buffer 2 μl  20 μl 
25Mm Mgcl2 4 μl 40 μl 
[18] 
 
0.1MDTT 2 μl 20 μl 
RNaseoutTM(400/μL) 1 μl  10μl 
 
VI. 9μl of 2X reaction mixture was added to each RNA/Primer from step3, mixed gently 
and collected after brief centrifugation and incubated at 42 oC for 2 minute. 
VII. 1μl of superscript TM II RT was added to each tube and then incubated for 50 minute 
at 42 oC. 
VIII. The reaction was ended at 70 oC for 15 minute and then chilled on ice. 
IX. By brief centrifugation the reaction was collected. To each tube, 1 μl of RNase H was 
added and incubated at 37 oC for 20 minute and then the reaction was used for PCR 
immediately. 
Quantative RT-PCR analysis 
In qRT-PCR florescence signal is continuously collected from one or more PCR over a range 
of cycles. Thus florescence signals coming out from each reaction are converted into a 
numerical value for each sample. In order to bind DNA florescent maker is used. Thus during 
the reaction as the number of copies increase, so the florescent intensity increases. SYBR 
green is a intercalating florescent dye, and it is the cheapest and simplest way in order to 
monitor a PCR in real time. The dye florescence only on binding to ds DNA. Using dye has 
one disadvantage, which is lack of specificity .From primer bank Database (Harvard) the gene 
specific primer sequence were obtained and the primers were synthesized by Sigma. All the 
primers were desalted. 
i. Procedure of mRNA qRT-PCR 
In order to perform PCR study, RNA must transcribed into cDNA by reverse transcription 
reaction. cDNA act as template for RT-PCR along with primers specific to a particular gene 
(Table 3). 
 
Table 3. Primer name and sequence length and its amplicon size 
Gene Sequence Amplicon size 
ACTB F- CATGTACGTTGCTATCCAGGC 250 
 R- CTCCTTAATGTCACGCACGAT  
COL1A2 F- GAGCGGTAACAAGGGTGAGC 92 
 R- CTTCCCCATTAGGGCCTCTC  
RRM2 F- CACGGAGCCGAAAACTAAAGC 129 
 R- TCTGCCTTCTTATACATCTGCCA  
[19] 
 
 
In Eppendorf Masterplex Real Time PCR, RT-PCR was carried out. 20ng cDNA was used 
per reaction. Primer concentration was normalized and gene specific forward and reverse 
primer pair was mixed. Each primer that is forward and reverse primer concentration in 
mixture was 9.5μl.  
I. Now the experiment was ready and the following PCR program was made on. 
Threshold frequency was 33%. The temperature cycle were(Table 4) taken as follows: 
Table 4. Temperature cycle for qRT-PCR 
Stage Temperature(oC) Time Cycle 
Stage 1 95 20 sec 1 
Stage2 95 
59 
68 
15 sec 
15 sec 
20 sec 
40 
Stage3 95 
60 
95 
15sec 
15sec 
15sec 
1 
 
II. cDNA was diluted to 1:20 ratio concentration and then primer was added. 
III. 10μl of a real time PCR reaction volume was made. 
IV. In each optional tube following mixture was made as follows (Table 5). 
 
 
Table 5.Reaction mixture for qRT-PCR 
SYBR Green Mix(2x) 95 μl 
cDNA stock (cDNA:dH2O) 40μl 
Primer pair mix(3.5μl each primer) 9.5μl 
 
V. With the help of in-built software, the RT-PCR result was analysed. 
VI.  The tubes were removed from the machine, after PCR is finished. 
  
[20] 
 
RESULTS AND DISCUSSIONS 
1. myc regulated miRNA 
To identify the transcriptional regulation of miRNAs by myc, 42 myc controlled miRNAs 
were obtained from TransmiR database and listed in (Table 7). Of these 7 miRNAs were 
found to be involved in STS and those were selected for further studies (Figure 6). The 
selected miRNAs were miR-34a, let-7b, let-7g, let-7, miR-22, miR-26a and miR-221(Figure 
5). 
Table 5: List of myc regulated miRNAs extracted from TransmiR 
TF miRNA miRNA tumor 
involvement 
Action type Reference 
MYC mir-106a Y Activation 17943719  
MYC mir-17 Y Activation 17943719 19066217  
MYC mir-18a Y Activation 17943719 19066217  
MYC mir-19a Y Activation 17943719 19066217  
MYC mir-19b Y Activation 17943719 19066217  
MYC mir-20a Y Activation 17943719 19066217  
MYC mir-221 Y Activation 17943719  
MYC mir-92a Y Activation 17943719 19066217  
MYC mir-195 Y Repression 18066065  
MYC mir-22 Y Repression 18066065  
MYC mir-29a Y Repression 18066065  
MYC mir-29c Y Repression 18066065  
MYC mir-26a Y Repression 18713946 19197161  
MYC let-7a Y Repression 19211792  
MYC let-7b Y Repression 19211792  
MYC let-7c Y Repression 19211792  
MYC let-7d Y Repression 19211792  
MYC let-7e Y Repression 19211792  
MYC let-7f Y Repression 19211792  
MYC let-7g Y Repression 19211792  
MYC let-7i Y Repression 19211792  
MYC mir-15a Y Repression 19211792  
MYC mir-16-1 Y Repression 19211792  
MYC mir-34a Y Repression 19211792  
[21] 
 
MYC mir-23a Y Repression 19219026  
MYC mir-23b Y Repression 19219026  
MYC mir-200 Y Regulation 19745813  
MYC mir-429 Y Regulation 19745813  
MYC mir-141 Y Regulation 19745813  
MYC mir-9 Y Activation 20173743  
20173740  
MYC mir-141 Y Regulation 20053927  
MYC mir-17 Y Regulation 20008931  
MYC mir-19a Y Regulation 20008931  
MYC mir-19b Y Regulation 20008931  
MYC mir-17 Y Repression 20878079  
MYC mir-20a Y Repression 20878079  
MYC mir-20b Y Repression 20878079  
MYC mir-106a Y Repression 20878079  
MYC mir-106b Y Repression 20878079  
MYC mir-93 Y Repression 20878079  
MYC mir-17 Y Upregulation 20643754  
MYC let-7 Y Repression 22388088  
MYC mir-29b n/a Repression 22249264  
MYC mir-26a n/a Repression 21941025  
MYC mir-26b n/a Repression 21941025  
MYC let-7a-1 n/a Repression 21903590  
MYC let-7f-1 n/a Repression 21903590  
MYC let-7d n/a Repression 21903590  
MYC miR-106b Y down-regulation 23028803  
MYC miR-25 Y down-regulation 23028803  
MYC miR-93 Y down-regulation 23028803  
[22] 
 
 
 
                    Figure 6: Mapping myc regulated miRNA with known miRNAs in STS 
                
 
                                    
                                        Figure 7: myc regulating miRNA reported in STS 
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2) miRNA-Target Selection 
 To study the downstream effects of myc-miRNA interaction, the validated targets of these 
seven miRNAs from miRecords, TransmiR and miRTarBase were selected. A total of 265 
targets were found (Figure 8). We compared these target gene list with DE genes in STS 
obtained from microarray analysis.  
 
 
Figure 8: myc-miRNA regulated network in STS 
3) Expression Data Analysis  
Microarray Data analysis - 1068 differentially expressed genes (DE) were obtained between 
myxofibrosarcoma and the control normal fat samples. Of these, 558 genes were found to be 
up-regulated and 510 genes were down-regulated in myxofibrosarcoma vs. control normal fat 
[24] 
 
samples. Hierarchical clustering of the DE genes showed the relatedness among the samples 
as all control samples clustered together and all sarcoma samples clustered together (Figure 9) 
 
                      
             Figure 9: Hierarchical clustering of Sarcoma and normal fat samples  
4) Novel DE gene identification for STS  
We obtained 265 genes which were the targets of those 7 miRNAs regulated by myc 
transcription factor. From microarray analysis we obtained the list of 1068 genes which were 
differentially expressed in Sarcoma than normal fat samples. By comparing those 2 sets of 
genes, we found out 12 target genes which were differentially expressed in STS (Figure 10). 
Those 12 genes are COL1A2, MYC, RRM2, TYMS, EMP1, CEBPB, MAOA, PTEN, EZH2, 
CDKN1C, FOS and ICAM1. 
[25] 
 
 
         Figure 10:  Comparison of myc regulated miRNA targets with DE genes in STS           
These 12 DE genes which were the targeted by 7 STS related myc-miRNAs were then compared with 
the list of known genes DE in STS obtained from Malacard database (Rappaport et al.). To this end 6 
genes were short listed for their association with STS and having altered expression in 
myxofibrosarcoma compared to normal fat cells (Figure 11). From myc-miRNA-target pathway 
enrichment study 6 novel genes were obtained, having altered expression in STS. Functional 
annotation of these genes were done and shown in (Table 6). 
 
Figure 11: Comparison of 12 DE myc-miRNA-targets with DE genes known in STS 
[26] 
 
Table 6: Significant gene ontology terms related to six novel altered genes 
 
Gene Name Enriched Database   Predicted Functional Association 
CEBPB BIOCARTA IL 6 signalling pathway 
GOTERM_BP_FAT regulation of cytokine production, transcription 
GOTERM_MF_FAT transcription activator  
SP_PIR_KEYWOR
DS 
transcription regulation, differentiation, DNA binding 
COL1A2 GOTERM_BP_FAT Skeletal system development, blood vessel 
development, vasculature development 
GOTERM_CC_FAT extracellular matrix,  
SP_PIR_KEYWOR
DS 
chromosomal rearrangement,  
EMP1 
 
GOTERM_BP_FAT cell proliferation, regulation of cell size, epidermis 
development, cell growth, 
GOTERM_CC_FAT cell fraction, membrane fraction 
INTERPRO Epithelial membrane protein EMP-1 
MAOA GOTERM_BP_FAT regulation of neurotransmitter levels, cellular amino 
acid derivative metabolic process 
COG_ONTOLOGY Amino acid transport and metabolism 
GOTERM_CC_FAT mitochondrial envelope, mitochondrial outer membrane 
GOTERM_MF_FAT amine oxidase activity, electron carrier 
activity, oxidoreductase activity 
SP_PIR_KEYWOR
DS 
Neurotransmitter 
degradation, oxidoreductase, transmembrane, 
RRM2 GOTERM_BP_FAT DNA metabolic process, DNA replication, nucleotide 
biosynthetic process 
KEGG_PATHWAY Purine metabolism, Pyrimidine metabolism,  
SP_PIR_KEYWOR
DS 
DNA replication, iron, metal-binding, oxidoreductase 
FOS BBID T_cell_receptor 
BIOCARTA Oxidative Stress Induced Gene Expression Via Nrf2, B 
Cell Survival Pathway, BCR Signalling Pathway,  IL2 
signalling pathway, IL3 IL6 signalling pathway, Insulin 
Signalling Pathway,  
GOTERM_BP_FAT DNA modification, DNA alkylation, DNA 
methylation, regulation of transcription 
KEGG_PATHWAY Pathways in cancer, Colorectal cancer 
These 6 genes are COL1A2, RRM2, EMP1, CEBPB, MAOA and FOS. The miRNA target 
interactions found were hsa-let-7g→COL1A2, hsa-let-7b→RRM2, hsa-miR-34a→EMP1, hsa-
miR-34a→CEBPB, hsa-miR-34a→MAOA and hsa-miR-26a→FOS. Out of these 6 targets, we 
experimentally validated COL1A2 and RRM2 as they are up-regulated in STS and their 
targeting miRNA were found to be down-regulated. Rest 4 genes were down-regulated in 
[27] 
 
STS.  Interactions of miRNA hsa-let-7g and hsa-let-7b are shown in Figure 12 and Figure 13 
below. 
 
Figure 12: Representing let-7b→ target Interactions. RRM2 has been highlighted in red. 
 
Figure13: Representing let-7g→target interactions. COL1A2 has been highlighted in red. 
 
           
[28] 
 
Further literature studies were done to explore genomic status and function of COL1A2 and 
RRM2 in detail. COL1A2 gene encodes one chain of type I collagen alpha-2(I) protein and 
found in most of the connective tissue. It is located at position 22.1 on chromosome number 
7.Up-regulation of this gene is already reported in various cancers like dermal fibroblasts, 
gastric cancer, colorectal carcinoma etc. Expression of this gene correlates with endogenous 
Tbx2 (T box family of transcription factor) in several fibroblast cell line, induce tumor 
angiogenesis and oncogenesis (Davis et al., 2008). Its suppression leads to decrease in 
vascular growth and its expression is necessary for angiogenesis. It can organize new blood 
vessels and may serve as important biomarker (Senger et al., 2002). RRM2 (ribonucleotide 
reductase M2) encodes ribonucleoside-diphosphate reductase subunit M2 which catalyses the 
formation of deoxyribonucleotides from ribonucleotide. Increase in RRM2 can induce VEGF 
(vascular endothelial growth factor). Thus it is predicted to be regulating the invasive and 
metastatic potential of tumors. Thus it helps in angiogenesis and critical to tumor malignancy 
(Zhang et al., 2009). 
 
5. Experimental Validation 
 
RNA Isolation 
260/280 ratio: It referes to the absorbance of RNA and DNA at 260 nm and 280 nm 
respectively. It is used to access the purity of DNA and RNA. Approximately 1:8 ratios is 
generally expected and accepted as “pure” for DNA and approximately 2.0 ratios is as “pure” 
form RNA. In either case, if the ratio is significantly lower it may indicate the presence of 
phenol, protein or other contaminants that absorb at or near 280nm. 
260/230 ratio: The 260/230 values for “pure” nucleic acid is generally higher than the 
respective 260/280 values. Expected 260/230 values are normally lies in the range of 2.0-2.2. 
If the ratio is significantly lower than the expected ratio, then it indicates that contaminants 
absorbing at 230 nm are present. 
qRT-PCR 
 
The qRT-PCR program used 59º as annealing temperature as the amplification for ACTB, 
COL1A2 and RRM2 was best at that temperature (Figure 14). 
 
[29] 
 
 
 
Figure 14: Cycle temperature and time for qRT-PCR. 
 
qRT-PCR melting curve analysis showed a single amplification product was formed for the 
COL1A2, RRM2 and ACTB as only a single peak was obtained for the respective genes. 
There was no nonspecific amplification detected (Figure 15). COL1A2 and RRM2 showed 
elevated expression w.r.t ACTB (Figure 16). 
 
 
    Figure 15: Melting temperature curve of COL1A2 and RRM2 with respect to ACTB. 
 
[30] 
 
             
  
Figure 16: Result of qRT-PCR analysis of COL1A2 and RRM2 gene. 
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CONCLUSIONS 
From myc targeting miRNA table we found out 7 miRNAs which are already reported in STS 
and obtained 265 targets of those miRNAs. Out of those 265 targets, 12 genes are having 
altered expression in STS and among them 6 genes are known and rest 6 are not yet validated 
in STS but they are having altered expression. From these 6 genes, 2 genes i.e. COL1A2 and 
RRM2 were selected for confirming their regulations in sarcoma cell lines through 
experimental validation. COL1A2 and RRM2 are reported to be over-expressed in other 
cancer systems. Through qRT-PCR, COL1A2 and RRM2 gene were found to be over-
expressed in STS. That signifies the study as targeting miRNAs of COLIA2 and RRM2 i.e. 
hsa-let-7g and hsa-let-7b respectively, were previously reported to be down-regulated in STS. 
As COL1A2 and RRM2 were reported earlier as an angiogenesis inducing factor in most 
cancer systems and critical to tumor malignancy, so we hypothesize that the over-expression 
of this gene in STS may contribute to its metastatic spread and lethality and this over-
expression can be attributed to altered expression of miRNA hsa-let-7g and hsa-let-7b that 
might have resulted in abnormal expression of MYC oncogene. 
 
 
 
 
 
 
 
 
 
 
 
[32] 
 
FUTURE PROSPECTIVES 
 
Based on the current findings, further studies can be performed to understand and confirm the 
role of COL1A2 and RRM2 genes in regulating STS thereby legitimizing its role in 
angiogenesis and metastasis. Understanding the basis of regulation of these mRNA and their 
targeting miRNA may provide a clue towards discovering RNA-based therapeutic approach 
for STS. The effectiveness of miRNA based fibrosarcoma therapy can be a land mark in 
fibrosarcoma studies. Therapeutic value of this study can be further assessed by over 
expressing miRNAs in sarcoma cell lines thereby checking the proliferation rate along with 
the expression of the target genes. After successful execution of these in cell lines, it can be 
extended further to validate in animal models in order to check the level of angiogenesis. This 
novel approach can thus prevent the cancer progression at the initial stages and hence can 
reduce the adverse effect of STS. Subsequent analysis of this novel miRNA-target pair will 
enhance our understanding to manipulate pathways for treatment of fibrosarcoma through 
microRNA mediated therapeutics. 
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